Literature DB >> 16436797

Intralipid prolongs survival in a rat model of verapamil toxicity.

Simon Tebbutt1, Martyn Harvey, Tonia Nicholson, Grant Cave.   

Abstract

OBJECTIVES: Verapamil is a lipid-soluble calcium channel blocker with significant mortality in overdose. Previous investigators have demonstrated the benefit of lipid emulsion therapy in ameliorating toxicity from lipid-soluble agents. The authors investigated the effect of Intralipid treatment in a rat model of verapamil toxicity.
METHODS: Thirty sedated Wistar rats were infused with verapamil at 37.5 mg/kg/h. Five minutes after the start of infusion, animals were treated with a bolus of either 12.4 mL/kg 20% Intralipid or 12.4 mL/kg 0.9% saline. Verapamil infusion was continued until the animals were killed. Respiratory rate, heart rate, and electrocardiography were sampled every 2.5 minutes throughout.
RESULTS: Survival was prolonged in the Intralipid-treated group (44 +/- 21 vs. 24 +/- 9 minutes; p = 0.003). The median lethal dose was increased in the Intralipid group (25.7 mg/kg [95% confidence interval {CI} = 24.7 to 26.7] vs. 13.6 mg/kg [95% CI = 12.2 to 15.0]). A less marked decrease in heart rate was observed during verapamil infusion in the Intralipid-treated group (6.8 beats/min [95% CI = 8.3 to 5.2] for Intralipid vs. 10.7 beats/min [95% CI = 12.6 to 8.9] for saline; p = 0.001).
CONCLUSIONS: Intralipid treatment prolongs survival and doubles median lethal dose in a rat model of verapamil toxicity. The mechanism of action remains to be elucidated.

Entities:  

Mesh:

Substances:

Year:  2006        PMID: 16436797     DOI: 10.1197/j.aem.2005.08.016

Source DB:  PubMed          Journal:  Acad Emerg Med        ISSN: 1069-6563            Impact factor:   3.451


  22 in total

1.  Intralipid fat emulsion decreases respiratory failure in a rat model of parathion exposure.

Authors:  Courtney Dunn; Steven B Bird; Romolo Gaspari
Journal:  Acad Emerg Med       Date:  2012-05       Impact factor: 3.451

2.  Intravenous lipid emulsion does not augment blood pressure recovery in a rabbit model of metoprolol toxicity.

Authors:  Alexander Browne; Martyn Harvey; Grant Cave
Journal:  J Med Toxicol       Date:  2010-12

Review 3.  Intravenous fat emulsion: a potential novel antidote.

Authors:  Danielle E Turner-Lawrence; William Kerns Ii
Journal:  J Med Toxicol       Date:  2008-06

4.  LIPAEMIC report: results of clinical use of intravenous lipid emulsion in drug toxicity reported to an online lipid registry.

Authors:  Grant Cave; Martyn Harvey; Johann Willers; David Uncles; Tim Meek; John Picard; Guy Weinberg
Journal:  J Med Toxicol       Date:  2014-06

5.  Survival of verapamil-poisoned rats treated with triiodothyronine.

Authors:  Michael J Lynch; Kenneth D Katz; Clifton W Callaway; Eric S Logue
Journal:  J Med Toxicol       Date:  2010-06

Review 6.  Management of Calcium Channel Blocker Toxicity in the Pediatric Patient.

Authors:  Jenna W Bartlett; Pamela L Walker
Journal:  J Pediatr Pharmacol Ther       Date:  2019 Sep-Oct

Review 7.  Intravenous lipid emulsion in clinical toxicology.

Authors:  Leelach Rothschild; Sarah Bern; Sarah Oswald; Guy Weinberg
Journal:  Scand J Trauma Resusc Emerg Med       Date:  2010-10-05       Impact factor: 2.953

8.  Intralipid infusion ameliorates propranolol-induced hypotension in rabbits.

Authors:  Martyn G Harvey; Grant R Cave
Journal:  J Med Toxicol       Date:  2008-06

9.  Pilot Trial of Intravenous Lipid Emulsion Treatment for Severe Nifedipine-Induced Shock.

Authors:  Christine M Murphy; Cliff Williams; Michael E Quinn; Brian Nicholson; Thomas Shoe; Michael C Beuhler; William P Kerns
Journal:  J Med Toxicol       Date:  2016-08-08

10.  Insulin Signaling in Bupivacaine-induced Cardiac Toxicity: Sensitization during Recovery and Potentiation by Lipid Emulsion.

Authors:  Michael R Fettiplace; Katarzyna Kowal; Richard Ripper; Alexandria Young; Kinga Lis; Israel Rubinstein; Marcelo Bonini; Richard Minshall; Guy Weinberg
Journal:  Anesthesiology       Date:  2016-02       Impact factor: 7.892

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.